Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the recipient of a significant increase in short interest in the month of ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...

这篇综述聚焦急性疼痛生物标志物，探讨其在遗传、炎症、神经传递等方面的研究进展，分析各类生物标志物对疼痛诊断、治疗及慢性疼痛预测的意义，为优化疼痛管理提供新思路，值得关注。 引言 急性疼痛作为机体对有害刺激的常见适应性反应，是身体可能 ...

Sangamo Therapeutics, with a market capitalization of $211.78 million, reported its earnings for Q4 2024, posting an EPS of -0.11, slightly missing the forecast of -0.10. Revenue came in at 7.55 ...